Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
9.50
-0.36 (-3.65%)
May 14, 2025, 10:06 AM - Market open
Maze Therapeutics Employees
Maze Therapeutics had 125 employees as of December 31, 2024.
Employees
125
Change
n/a
Growth
n/a
Revenue / Employee
$1,340,000
Profits / Employee
$27,240
Market Cap
416.06M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 125 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MAZE News
- 1 day ago - Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference - GlobeNewsWire
- 6 weeks ago - Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights - GlobeNewsWire
- 3 months ago - Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease - GlobeNewsWire
- 3 months ago - U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs - Seeking Alpha
- 3 months ago - Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut - Reuters
- 3 months ago - Biotech firm Maze Therapeutics raises $140 million in US IPO - Reuters
- 3 months ago - Maze Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewsWire
- 3 months ago - Maze Therapeutics targets up to $728 mln valuation in US IPO - Reuters